Velcalcetide
Parsabiv (velcalcetide) is a protein pharmaceutical. Velcalcetide was first approved as Parsabiv on 2016-11-11. It has been approved in Europe to treat secondary hyperparathyroidism. It is known to target extracellular calcium-sensing receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | 3 | — | 9 | 1 | — | 13 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | 3 | — | 7 | 1 | — | 11 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | 8 | 1 | — | 10 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | 6 | 1 | — | 8 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | — | 1 | — | 1 |
| Cardiomegaly | D006332 | EFO_0002503 | I51.7 | — | — | — | 1 | — | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | 7 | — | — | 8 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 1 | — | — | — | 2 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Velcalcetide |
| INN | etelcalcetide |
| Description | Etelcalcetide is an oligopeptide. |
| Classification | Protein |
| Drug class | peptides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N[C@H](CSSC[C@H](N)C(=O)O)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 1262780-97-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545184 |
| ChEBI ID | — |
| PubChem CID | 71511839 |
| DrugBank | DB12865 |
| UNII ID | 60ME133FJB (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CASR
CASR
Organism
Homo sapiens
Gene name
CASR
Gene synonyms
GPRC2A, PCAR1
NCBI Gene ID
Protein name
extracellular calcium-sensing receptor
Protein synonyms
parathyroid Ca(2+)-sensing receptor 1, Parathyroid cell calcium-sensing receptor 1, PCaR1
Uniprot ID
Mouse ortholog
Casr (12374)
extracellular calcium-sensing receptor (Q9R1Y2)
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,742 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use